> Quality-control fears notwithstanding, China has knocked India off the catbird seat as pharma's favorite spot for outsourcing. Report
> South San Francisco-based Anesiva says it has received a term loan of $30 million in a financing deal led by Oxford Finance and co-funded by CIT Healthcare and Compass Horizon Funding Company. Anesiva release
> RegeneRx Biopharmaceuticals is looking to partner up on its cystic fibrosis therapy RGN-457. RegeneRx report
> Circassia has launched a further phase II clinical study of its ToleroMune technology in the field of cat allergy. Cairassia release
> In last night's vice presidential debate, moderator Gwen Ifill asked which was worse, a nuclear Iran or unstable Pakistan. Some would say that's the difference between a rock and a hard place. But pharma execs could echo Rep. Rahm Emanuel, who's raising the specter of no R&D tax credit versus no DTC tax breaks. DTC report
> In its ongoing fight with Roche, Amgen now has stronger backing from a federal court. The U.S. District Court in Boston ruled yesterday that Amgen should get a permanent injunction against Roche's anemia med Mircera. This decision cements a previous jury's conclusion that Mircera violates Amgen's patents. Mircera report
> A potentially deadly brain infection has reared its head in another drug population. This time, Genentech is warning doctors that a patient treated with its psoriasis drug Raptiva has developed progressive multifocal leukoencephalopathy, or PML. Raptiva report
> Late last week a group of the world's top health officials met to put the finishing touches to a multibillion-dollar campaign aimed at wiping out malaria. Report
And Finally... Adolescent males who possess a certain type of variation in a specific gene are more likely to flock to delinquent peers, according to a study led by Florida State University criminologist Kevin M. Beaver. Release